MENTIS CURA EHF

Their core work

Mentis Cura is an Icelandic private mental health company that bridges clinical practice and neuroscience research. Their work spans two distinct but related domains: understanding pain at the neurological level (through DOLORisk) and studying how social and cognitive development unfolds in early childhood, particularly in children at risk for autism and ADHD (through SAPIENS). They contribute clinical expertise and likely patient access or assessment capabilities to large European research consortia. As a small specialist SME, they function as a real-world clinical anchor in academic networks — bringing applied knowledge of neurodevelopmental and neurological conditions into research settings.

What they specialise in

How they've shifted over time

In their first H2020 project (DOLORisk, 2015–2020), Mentis Cura was embedded in the neurology and pain science space, contributing to a funded study on chronic neuropathic pain — a field relevant to neurology clinics and pain management services. By their second project (SAPIENS, 2019–2023), the focus had shifted markedly toward early childhood neurodevelopment, with specific attention to autism, ADHD, and the social brain — a pivot from adult-onset neurological conditions toward pediatric developmental psychiatry. This trajectory suggests the organization is deepening its specialization in mental health and neurodevelopmental conditions, moving upstream toward prevention and early intervention.

Mentis Cura is moving toward early-life neurodevelopmental research — autism, ADHD, and social brain development — which positions them as a potential clinical partner for any consortium working on pediatric mental health, developmental screening tools, or digital diagnostics for childhood disorders.

How they like to work

Mentis Cura has never led an H2020 project — they join as participant or third-party partner, suggesting a deliberate choice to contribute specialist knowledge rather than manage large consortia. Despite their small size, they have connected with 27 unique partners across 12 countries, which indicates they are a valued specialist node in European research networks rather than an isolated actor. Working with them likely means engaging a focused clinical contributor who brings Icelandic patient populations, mental health practice context, or neurodevelopmental assessment expertise to the table.

Mentis Cura has engaged with 27 consortium partners across 12 countries despite having only two projects, reflecting participation in large multi-site European research networks. Their geographic reach extends well beyond Iceland, spanning the EU research area with no apparent single-country dominance.

What sets them apart

Mentis Cura occupies a rare position as an Icelandic clinical SME active in two distinct neuroscience domains — chronic pain and childhood neurodevelopment — which gives them unusual cross-disciplinary credibility for a small private company. Iceland's nationally comprehensive health registries and genetically well-characterized population are a significant asset for clinical research, potentially making Mentis Cura a high-value partner for studies requiring clean longitudinal patient data. For consortium builders, they offer a combination of real-world clinical grounding and established European research networks that few Icelandic SMEs can match.

Highlights from their portfolio

• SAPIENS
  A Research Excellence (MSCA-ITN) project on the social brain and autism/ADHD early detection — notable for its developmental focus and the breadth of its keyword set, which maps directly onto the most pressing unmet needs in pediatric mental health.
• DOLORisk
  Mentis Cura's only directly funded H2020 project (EUR 177,500), embedded in a large European RIA on neuropathic pain risk — their earliest and most financially significant EU research engagement.